Ireland
--:--IST
Enrolling by invitation Not applicable

Adipose-derived Stem Cells in Treatment of Esophageal Strictures

NCT07913646 · tracked via the Priya Life Science Norway tracker
Phase
Not applicable
Started
2026-11-01
Last updated
2026-11-03

Condition(s) studied

Esophageal Stenosis Acquired

Investigational drug(s) / intervention(s)

Adipose-derived stem cells and stromal vascular fraction

Adipose-derived stem cells and stromal vascular fraction: Adipose-derived stem cells and stromal vascular fraction will be injected into benign esophageal strictures in all patients (n=10).

Study summary

The goal of this clinical trial is to examine the effect of injection of adipose tissue derived stem cells in benign esophageal strictures in patients who have previously required at least 10 balloon dilations without satisfactory results on symptoms and esophageal diameter. This pilot trial will primarily examine the effects of the intervention on resolution of dysphagia and achieving a diameter ≥13 mm of the esophageal lumen. The trial will investigate dysphagia after two weeks, one, two and six months and diameter of the esophagus after one, two and six months. The trial will also record the following secondary outcomes: stricture diameter at each endoscopy, time to stricture requiring new dilation due to symptoms and diameter \< 13 mm as well as adverse events.

Participants will be required to undergo a procedure which starts by harvesting of adipose tissue from the abdominal subcutaneous fat. A concentrate of stem cells and supportive cells will be prepared on site, before balloon dilation of the esophageal stricture and then injection of the cell preparation within the dilated stricture.

Participants will then undergo follow-up after:

* Two weeks: telephone call, open question concerning side effects and dysphagia score
* One month: dysphagia score and upper endoscopy with measured diameter of stricture
* Two months: dysphagia score and upper endoscopy with measured diameter of stricture
* Six months: dysphagia score and upper endoscopy with measured diameter of stricture.

The patient will at any timepoint contact the hospital if symptoms occur and an endoscopy with dilation is needed (rescue dilation). The time from intervention to rescue dilation will then be recorded.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Benign esophageal stricture diagnosed by endoscopy and histology Refractory stenosis defined as previous balloon or bougie dilation treatment at least ten times 2. Length of stricture up to 3.0 cm Exclusion Criteria: * The use of platelet inhibitors other than acetylsalicylic acid, BMI \< 18 or \> 35, liver cirrhosis, other significant comorbidity such as COPD GOLD 3-4, unstable coronary heart disease, current malignant disease. * WHO performance status \>1. * Previous scarring in abdominal subcutaneous tissue making fat grafting difficult * Previous non-adherence to scheduled follow-up * Unable to understand Norwegian or unable to sign informed consent

Primary outcome measure(s)

  • Resolution of dysphagia and esophageal stricture — Six months
    Resolution of dysphagia defined as Mellow Pinkas score = 0 or an improvement of ≥ 2 points and esophageal luminal diameter ≥ 13 mm

Trial sites (1)

FacilityCityRegionStatus
Oslo University Hospital, Ullevål Oslo Oslo
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07913646 on ClinicalTrials.gov ↗ ← All trials in Norway